Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care

OBJECTIVE: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine storm”. Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear, and the ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Quartuccio, Luca, Sonaglia, Arianna, McGonagle, Dennis, Fabris, Martina, Peghin, Maddalena, Pecori, Davide, De Monte, Amato, Bove, Tiziana, Curcio, Francesco, Bassi, Flavio, De Vita, Salvatore, Tascini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227535/
https://www.ncbi.nlm.nih.gov/pubmed/32570043
http://dx.doi.org/10.1016/j.jcv.2020.104444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227535/
https://www.ncbi.nlm.nih.gov/pubmed/32570043
http://dx.doi.org/10.1016/j.jcv.2020.104444

Ejemplares similares